Clin2
NCT06639282Possibly a fitRecruiting

Testing siponimod for mild Alzheimer's dementia

Alzheimer DiseaseMild Alzheimer DiseaseMCI With Increased Risk for Alzheimer DiseaseCognitive Impairment, Mild

Part of Brain & nervous system, Mental health clinical trials.

This study tests if a medicine called siponimod, already used for multiple sclerosis, can help people with mild Alzheimer's dementia. You will take a pill daily and be monitored closely for safety and cognitive changes.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
105 people
Ages
50 years to 85 years
Study type
Interventional

Who can take part

  • You must be between 50 and 84 years old.
  • You have a diagnosis of mild Alzheimer's dementia.
  • You need a family member or friend who can help with study visits and medications.
  • You must be able to take pills by mouth and attend all study visits.
  • You cannot have certain heart, immune, or other serious health issues.
  • You must have had a recent brain scan (CT or MRI) showing no other cause for memory problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05413655Recruiting· Phase 2
Oral drug for mild Alzheimer’s disease symptoms

This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.

Taipei
NCT06995573Recruiting· Phase 1/Phase 2
Testing a new Alzheimer's drug (NSC001) for safety and early effectiveness

This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.

Salzburg, State of Salzburg
NCT04902703Recruiting· Phase 2
GM-CSF drug trial for mild to moderate Alzheimer’s disease

This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.

Aurora, Colorado
NCT06177028Not yet recruiting· Phase 2
Testing lenalidomide for mild cognitive impairment

This trial tests an oral drug called lenalidomide (often used for immune conditions) to see if it can help people with early memory loss due to Alzheimer's. You would need a study partner, be willing to have spinal taps and brain scans, and have a positive amyloid PET scan.

NCT06862960Recruiting· Phase 2
Ozanimod for moderate Alzheimer's disease

This trial tests whether a daily pill called ozanimod can help people with moderate Alzheimer's disease. The study monitors changes in thinking and memory over time and requires a study partner who can join visits.

Fuzhou, Fujian
NCT06761066Not yet recruiting
Testing NVP-NK4146 for mild cognitive impairment due to Alzheimer's

This study tests a new medicine, NVP-NK4146, for people with mild cognitive impairment (MCI) due to Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.

Hear when a new Mild Alzheimer Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.